New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in Pharmacological Research, show that an innovative drug effectively prevents prostate tumors from spreading to an advanced and incurable stage in the bones. The targeted small molecule inhibitor, IVMT-Rx-4, also enhances standard-of-care chemotherapy treatment for the disease, offering significant potential for a paradigm shift in the treatment of metastatic tumors.
This article was originally published on MedicalXpress.com
